
The Top Holding for CalPERS, America's Largest Public Pension Fund, Is the Closest Thing You'll Find to a Guaranteed Investment on Wall Street
There's nothing more important to investors than data -- and they're rarely, if ever, lacking for it on Wall Street. Between earnings reports, regular U.S. economic data releases, and Donald Trump's administration changing its tune on tariff and trade policy on a seemingly regular basis, there's always something for investors to dive into and learn.
May 15 marked one of these pivotal data releases for investors.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
No later than 45 calendar days following the end to a quarter, institutional investors managing at least $100 million are required to file Form 13F with the Securities and Exchange Commission. A 13F provides a snapshot for investors that allows them to see which stocks, exchange-traded funds (ETFs), and (select) options contracts Wall Street's most-prominent money managers have been buying and selling. It's a nice way to uncover which securities and trends are piquing the attention of big-money investors.
But there's a big world of investment dollars that extends beyond Berkshire Hathaway 's Warren Buffett and select billionaire fund managers -- and it pays to know what these funds are holding.
For example, the California Public Employees' Retirement System, commonly known as CalPERS, manages north of $500 billion in assets on behalf of its more than 2 million members, which includes public employees, retirees, and their families. CalPERS spreads its investment capital across a broad swath of asset classes, including fixed income (e.g., Treasury bonds), private debt, private equity, and of course, public equities (stocks and ETFs).
Though CalPERS closed the March-ended quarter with north of 1,100 securities in its portfolio, it's the top holding for America's largest pension fund that really stands out and delivers with long-term consistency.
America's largest pension fund owns pieces of many of America's most-influential businesses
Based on CalPERS' 13F, its fund managers were overseeing approximately $143.1 billion in invested assets as of the end of March. With this being a highly diversified pension fund, only 14 of these positions equated to 1% or more of invested assets.
But what a majority of these leading positions have in common is that they're Wall Street's most-influential businesses. Excluding Saudi Aramco, which isn't traded on U.S. stock exchanges, eight of the 10 public companies to have reached a $1 trillion (or greater) valuation are among these 14 positions, with only Tesla and Taiwan Semiconductor Manufacturing missing.
For instance, Apple (NASDAQ: AAPL) is the second-largest holding for CalPERS (5.4% of invested assets), based on its 13F. The roughly 34.66 million shares held equated to almost $7.7 billion in market value at the end of March. Though Apple's growth heyday might be in the rearview mirror, it's still a cash-generating machine thanks to its top-selling iPhone and its high-margin, subscription-driven services segment. Also, no public company has repurchased more of its own stock than Apple.
Artificial intelligence (AI) giant Nvidia (NASDAQ: NVDA), which briefly became the most-valuable public company by market cap, is CalPERS' No. 4 holding by market value (4.4% of invested assets). Nvidia's Hopper (H100) graphics processing unit (GPU) and Blackwell GPU architecture are primarily responsible for overseeing generative AI solutions and the training of large language models in high-compute data centers. By one estimate, AI can add $15.7 trillion to the global economy come 2030, and Nvidia is at the center of this growth trend.
The point being that many of CalPERS' biggest positions are tied to businesses that are instrumental to the ongoing success of the American and global economy.
But it's CalPERS' top holding that has an as-of-now perfect track record of delivering for long-term investors.
CalPERS' top holding has (thus far) been a guaranteed moneymaker
Though CalPERS' $143.1 billion portfolio is primarily comprised of individual stocks, the largest holding for America's top pension fund is an ETF: the Vanguard S&P 500 ETF (NYSEMKT: VOO) (7.9% of invested assets).
The beauty of ETFs is they can provide instant diversification or concentration, depending on your preference, with the click of a button. In this instance, the Vanguard S&P 500 ETF attempts to mirror the performance of the benchmark S&P 500 (SNPINDEX: ^GSPC).
Instead of having to buy 503 separate securities -- three S&P 500 companies have two classes of shares, which is why there are currently 503 components and not an even 500 -- and weight them appropriately to effectively match the returns of the S&P 500, the Vanguard S&P 500 ETF does this for investors with the click of the buy button.
In return for this ease of investment, investors pay various fees in the form of the net expense ratio. These fees cover the costs of overseeing the fund, marketing, and so on. Generally, the more active the turnover in the fund, the higher the net expense ratio.
The two biggest S&P 500 index funds by net assets are the Vanguard S&P 500 ETF and the SPDR S&P 500 ETF Trust (NYSEMKT: SPY). The SPDR S&P 500 ETF Trust was the first ETF to be listed on a national stock exchange.
Although the Vanguard S&P 500 ETF and SPDR S&P 500 ETF Trust effectively mirror the returns of the benchmark S&P 500, the two have one notable difference: their net expense ratios. The SPDR S&P 500 ETF Trust has a low net expense ratio of 0.09%. This means $0.90 of every $1,000 invested will be kept for various fees. Meanwhile, the Vanguard S&P 500 ETF has a net expense ratio of just 0.03%. While six hundredths of a percent might not sound like much, it can add up over multiple decades as your investment grows.
But what really makes the Vanguard S&P 500 ETF special is its, thus far, guaranteed long-term returns.
To preface, nothing is concretely a given when it comes to the stock market. Neither I nor any analyst can tell you with 100% certainty what comes next for stocks. But S&P 500 tracking indexes like the Vanguard S&P 500 ETF are the closest thing to an investment guarantee on Wall Street.
^SPX data by YCharts. The above S&P 500 chart only goes back as far as 1950.
Every year, the analysts at Crestmont Research update a data set that examines the rolling 20-year total returns, including dividends, of the benchmark S&P 500 dating back to the start of the 20th century. Even though the S&P wasn't officially incepted until 1923, researchers were able to track the performance of its components in other major indexes from 1900 to 1923 to obtain the relevant total return data. This resulted in 106 rolling 20-year periods to examine (1900-1919, 1901-1920, 1902-1921, and so on, to 2005-2024).
What Crestmont Research found was that all 106 rolling 20-year periods produced a positive annualized return. Hypothetically, if you had purchased an S&P 500 tracking index at any point between 1900 and 2005 and simply held for 20 years, you made money every time. It didn't matter if you purchased at the top of a bull market, held through a recession or depression, or navigated through a war or pandemic -- you would have grown your wealth every time.
Arguably no stock market investment has delivered with more long-term consistency than S&P 500 index funds – and no S&P 500 ETF has a more favorable net expense ratio than the Vanguard S&P 500 ETF.
Should you invest $1,000 in Vanguard S&P 500 ETF right now?
Before you buy stock in Vanguard S&P 500 ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vanguard S&P 500 ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,389!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $830,492!*
Now, it's worth noting Stock Advisor 's total average return is982% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
an hour ago
- CBC
Alberta asks for a West Coast pipeline as a nation-building project
The federal government has tabled a signature piece of legislation designed to invest in what Prime Minister Carney is referring to as 'nation-building projects.' The CBC's Sam Brooks takes us into how the Alberta government is responding.


Globe and Mail
2 hours ago
- Globe and Mail
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Disrupting the healthcare market Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk 's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Going abroad and personalization Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. HIMS Gross Profit Margin data by YCharts. Should you buy Hims & Hers stock? A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025


Globe and Mail
2 hours ago
- Globe and Mail
Better Artificial Intelligence (AI) Stock: CoreWeave vs. Nvidia
There will prove to be many winners as artificial intelligence (AI) infrastructure continues to grow and AI end-uses expand. Nvidia (NASDAQ: NVDA) has been the Wall Street darling surrounding everything AI for the past two years. CoreWeave (NASDAQ: CRWV) has been getting the love most recently, though. Shares of the AI hyperscaler providing cloud services have soared about 185% in just the past month as of this writing. Nvidia stock has increased 24% in that time. CoreWeave just went public in late March, and the shares have jumped about 270% since that initial public offering (IPO). Investors may wonder if Nvidia's shine is fading, and it's time to buy CoreWeave instead. I'd argue that is flawed thinking, however. The growth isn't over for Nvidia Investors may be taking a breather after the early exponential gains in Nvidia stock. Growth in the business itself has also slowed, though that was inevitable. Sales of its advanced chips in the data center segment had been growing like a weed. Revenue in that segment has been increasing in each consecutive quarter for the last two years. In the most recent fiscal quarter, that growth rate slowed to 10%, though, as seen below. Despite that trend, it's clear AI demand hasn't yet peaked. Remember, these are still sequential quarterly increases in data center sales. For perspective, that fiscal first-quarter revenue was a 73% jump compared to the prior year period. Management also guided investors to expect further revenue growth in the current quarter. So, while an unsustainable growth rate slows, the company is still solidly in growth mode. Nvidia is more ubiquitous than you might think That's because it's not just Nvidia's advanced GPU and CPU chips driving sales and expanding AI infrastructure. Its AI ecosystem includes interconnect technologies, the CUDA (compute unified device architecture) software platform, and artificial intelligence processors that are part of many different types of architectures. CEO Jensen Huang recently touted Nintendo 's new Switch 2 gaming console, for example. The unit includes Nvidia's AI processors that Huang claims "sharpen, animate, and enhance gameplay in real time." Nvidia has a broad array of customers. As AI factories and data centers are built, it will continue to be a major supplier and one that investors should benefit from owning. Nvidia also invests in the AI sector. It makes sense to look at where the AI leader itself sees future gains. Nvidia thinks CoreWeave is a good investment One of the AI companies in which Nvidia holds a stake is CoreWeave. Nvidia should know CoreWeave well, too, as an important customer. CoreWeave leases data center space to companies needing the scalable, on-demand compute power it has control of from the 250,000 Nvidia chips it has purchased. It's a desirable option for enterprises that require significant computational power to process large amounts of data efficiently. There appears to be plenty of demand. But there is plenty of risk for investors, too. It just announced a new lease agreement to further increase capacity. Applied Digital, a builder and operator of purpose-built data centers, has agreed to deliver CoreWeave 250 megawatts (MW) of power load on a 15-year term lease at its recently built North Dakota data center campus. CoreWeave has the option to expand the load by an additional 150 MW in the future. Demand is quickly driving growth for CoreWeave. That's led investors to jump in and drive the stock higher in recent months. Valuation is just one major risk with CoreWeave. Customer concentration is another. Last year, Microsoft accounted for nearly two-thirds of revenue. CoreWeave also disclosed that 77% of 2024 revenue came from just its top two customers. CoreWeave is also spending massive amounts of capital to grow AI cloud capacity. It had about $5.4 billion of liquidity available as of March 31 and raised another $2 billion from a late May debt offering. That's approximately its level of capital expenditure in just the first quarter alone, though. CoreWeave has the risk, Nvidia has the profits That spending may pay off. But there are risks there as well. Customers could develop their own AI infrastructure or could redesign systems that don't require its services. CoreWeave stock also trades at a high valuation after the stock has soared. It recently had a price-to-sales (P/S) ratio of about 30. That could be cut in half this year with its strong sales growth, but it isn't earning any money yet. At the same time, Nvidia sports a price-to- earnings (P/E) ratio of about 30 based on this year's expected profits. Remember, too, that as CoreWeave grows, so do Nvidia's profits. Applied Digital CEO Wes Cummins said that its leased North Dakota data center campus will be full of Nvidia Blackwell class servers. I think the risk profile, financial picture, and massive potential for Nvidia make it the better AI stock to buy now. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025